Clinical Trials About "proof concept study effects total cfDNA content solutions" RSS

04:00 EST 18th February 2020 | BioPortfolio

We list hundreds of Clinical Trials about "proof concept study effects total cfDNA content solutions" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "proof concept study effects total cfDNA content solutions" on BioPortfolio

We have published hundreds of proof concept study effects total cfDNA content solutions news stories on BioPortfolio along with dozens of proof concept study effects total cfDNA content solutions Clinical Trials and PubMed Articles about proof concept study effects total cfDNA content solutions for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of proof concept study effects total cfDNA content solutions Companies in our database. You can also find out about relevant proof concept study effects total cfDNA content solutions Drugs and Medications on this site too.

Showing "proof concept study effects total cfDNA content solutions" Clinical Trials 1–25 of 31,000+


Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis

Liquid biopsy has been widely used in the diagnosis and treatment of tumors, and cfDNA has always been a hot spot in clinical research. Previous studies have shown that cfDNA may be associated with postoperative recurrence of gastric cancer, but it is rarely reported whether cfDNA is associated with the survival of gastric cancer. The purpose of this study was to assess the relationship between cfDNA and survival in advanced gastric cancer

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

Phase IIa, open clinical trial, pilot, single arm and proof of concept.

Proof-of-concept Study on Disinfection and Healing Acceleration Capabilities of 222nm Wave Length Narrow Band Ultraviolet Lighting Device

The threat of MRSA and multi-drug resistant pathogens have been growing in recent years. A new means of countering the infectious threat is required and one such modality is the use of UV light for disinfection. The aim of the study is to proof the efficacy of the 222nm UV light in disinfection on patients with sacral sores. This is a first in human proof-of-concept study

Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib

The aim of this trial is to investigate whether quantitative analysis of the total concentration of circulating free deoxyribonucleic acid (cfDNA) and of the cfDNA integrity index (DII) (Intplex®) may reflect hepatocellular carcinoma (HCC) tumor dynamics or response for patients treated by Sorafenib or Regorafenib and if it could be used as a tool for patient management under targeted therapy.

Early Detection of Relapses in Stage IV Colorectal Cancer Patients

This study is a prospective, multicenter, observational study on metastatic, operable colorectal cancer to evaluate the proof of concept of the cfDNA analysis for the early detection of recurrences

A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G)

The primary purpose of this proof of concept clinical study is to evaluate the efficacy and safety of the study drug, ACH-0144471, in participants who have been diagnosed with either C3GN or dense deposit disease (DDD) based on renal biopsy. Participants will be randomized 1:1 to receive either study drug ACH-0144471 or placebo for a period of 6 months.

Study in Detection cfDNA for the Early-stage Diagnosis of Acute Rejection Post-renal Transplantation

Acute rejection (AR) is still one of the major complications after kidney transplantation. The current diagnosis measure for AR is primarily pathological puncture test and hematuria biomarker detection, yet due to their inferior performance on timeliness, the allograft kidneys usually have been in severe conditions when the diagnoses take place. Donor derived cell free DNA (dd-cfDNA) is utilized as a measure for "liquid biopsy", it can predict acute rejection at very early peri...

TraceBook: the Clinical Proof of Concept on the Intensive Care.

The effectiveness of current checklists is hampered by lack of acceptance and compliance. Recently, a new type of checklist with dynamic properties has been created to provide more specific checklist items for each individual patient. The proof of concept of this dynamic clinical checklist (DCC; BJA 2017 (DOI: 10.1093/bja/aex129)) was tested in a simulation trial with improved outcomes and high acceptance scores. The purpose of this study is to investigate if the outcomes of th...

BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 in adult patients with AS, in order to provide clinical proof of concept and to select dose (s) for confirmatory clinical trials.

NCAMR-CAMR Allosure Study

Heart Transplant recipients at Tampa General Hospital heart transplant program who have pAMR1(H+) or pAMR1(I+) rejection will have a DD-cfDNA /GEP sample obtained at the time of the rejection. The DD-cfDNA/GEP will then be drawn every month post treatment for the rejection until the DD-cfDNA/GEP level returns to normal. A total of fifteen recipients with pAMR1(H+) and fifteen recipients with pAMR1(I+) rejection will be included in the study which will last two years. The presen...

Validation of Ingestible Capsule to Study Small Bowel

Proof of concept study to validate the ability of the ingestible capsule to gather samples from the small bowel for microbiome analysis in adults.

A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)

This study will be a randomised, double blind, placebo controlled, 3-way, incomplete block crossover study to evaluate the effect of single and repeat doses of levocabastine, FF, placebo and a FDC of FF/levocabastine administration in AR subjects. The total expected study duration for each individual participating in the study will be a maximum of up to 20 weeks (including the screening and follow-up). This will be a three period study and subjects will be assigned to a sequenc...

PROOF: PROtein OverFeeding Effect on Body Weight

This study is designed to determine the effects of dietary protein content on overfeeding.

A Phase IIa Proof-of-Concept Study of NC-503 in Patients With Type II Diabetes

The main objectives of the current study are to establish the safety and clinical proof-of-concept of NC-503 in inadequately controlled patients with Type 2 diabetes and features of metabolic syndrome treated with either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent.

A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

The primary purpose of this open-label, Phase 2 proof of concept study is to evaluate the efficacy of 12 months of oral ACH-0144471 in participants with C3G or IC-MPGN based on renal biopsy results and the number and percentage of participants with an improvement relative to baseline in clinical manifestation(s) of C3G (proteinuria and reduced estimated glomerular filtration rate [eGFR]).

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease

This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase I/II, randomized, multicenter, dose escalation, double-blind, imitation surgery, first-in-human (FIH) study.

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a

Phase IV, proof-of-concept, randomized, open-label, multi-center, two-arm, 9-month study to evaluate the neuroprotective effects of Natalizumab (TYSABRI®) or Interferon beta-1a (AVONEX®) treatments initiated at the time of acute optic neuritis (AON) as measured by RNFL thickness from Optical Coherence Tomography in patients with Relapsing Remitting Multiple Sclerosis (RRMS).

Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study

MRI findings after successful PAE in patients suffering from BPH suggest a complete necrosis of the prostate after this intervention. Thus, PAE might also play a role in the treatment of prostate cancer. This proof of concept study assess the impact of PAE in patients with proven prostate cancer.

Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study

This study is a proof of concept study to confirm in a standardized manner the therapeutic efficacy of roflumilast in type 2 diabetes mellitus patients.

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of interstitial fibrosis (IF) and tubular atrophy (TA) seen in biopsy specimens. Here, we will study the utility of dd-cfDNA to predict rejection in pancreas and pancreas-kidney recipi...

Proof of Concept of Adapted PD in Children (PC-AAPD)

The purpose of this study is to validate the concept of adapted automated PD a modified Peritoneal Equilibration Test (PET), will be performed in children on chronic PD. Instead of a single 4 hour standard dwell, two double mini PET using the same type and total volume of dialysate and the same total dwell time (150min) will be performed in randomised sequence. An double mini test consists of two identical dwells, reflecting routine PD, the other one of a short small dwell foll...

Methylation of cfDNA in Diagnosing and Monitoring Pulmonary Nodule

Patients found pulmonary nodules by CT screening by will be enrolled in this study prospectively. Plasma cfDNA sequencing of these patients will be used to diagnose and monitor benign and malignant pulmonary nodules.

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.

A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone

To compare the effectiveness of a 90-day Copaxone® adherence enhancement program for a sample of MS patients who are at high risk of nonadherence and receive support from Shared Solutions® and their MS Center versus those who receive support only from Shared Solutions®.

A Double-Blind, Randomized, Placebo Controlled, Clinical Trial of an Antiplaque Chewing Gum (30 mg) - Phase 2 Proof of Concept in a Generally Healthy Patient Population

This study is a Phase 2 two-armed placebo-controlled, double-blind, randomized (1:1), multiple dose, single center study to evaluate the safety and proof of concept in a chewing gum formulation 3 times per day over 4 treatment days.

More From BioPortfolio on "proof concept study effects total cfDNA content solutions"

Quick Search